Recognizing the key role of IL‐6 in stroke pathogenesis, alongside its complicated signaling mechanisms, proceeding with individualized analysis of time‐dependent predominant signaling pathways in each patient prior to initiating IL‐6‐based treatments may aid to achieve the cytokine's therapeutic outcomes in stroke. This evidence concerns the gene IL6 and Stroke.